ArticleFrontiers in medicine2026
Construction of a novel risk model for esophageal squamous cell carcinoma associated with purinergic signaling pathways and chemoradiotherapy sensitivity genes.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) significantly impacts public health. Variability exists in patients' responses to chemoradiotherapy (CRT), and the role of purinergic signaling (PS) in ESCC, related to tumor migration, remains unclear. Methods: Survival-related genes among PS-related genes were identified using univariate Cox analysis. Patients from The Cancer Genome Atlas (TCGA)-ESCC dataset were categorized based on optimal scoring thresholds. Differential expression analysis was employed to identify differentially expressed genes (DEGs) between tumors and controls and across scoring groups. Intersecting genes from DEGs were identified and further analyzed in the GSE45670 dataset to identify genes associated with CRT sensitivity, which were designated as candidate genes. A prognostic signature was developed, and gene set enrichment analysis (GSEA), mutation analysis, immune infiltration, and drug sensitivity were implemented. In addition, we used Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) for experimental validation to further screen potential anti-tumor drug targets. Finally, the expression of prognostic signature genes in pan-cancer were explored. Results: A total of four prognostic signature genes (ANXA10, ERICH5, HRG, and AMN) were identified. GSEA linked the risk group to pathways like cell adhesion molecules. Mutational analysis suggested a potential missense mutation in ANXA10. High-risk patients were associated with increased infiltration of plasmacytoid dendritic cell and T follicular helper cells. Drugs like VX.702 and BMS.754807 were more effective in the high-risk group. In esophageal cancer, ANXA10 was remarkably down-regulated, and HRG was up-regulated. ESCC tumor tissues exhibited markedly decreased AMN and ERICH5 expression but increased HRG compared to normal controls. Conclusion: This study identified prognostic signature genes associated with CRT and PS in ESCC and constructed a risk model that may predict patient survival, which could provide valuable insights for future research on ESCC diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.